Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PureTech Health plc - American Depositary Shares
(NQ:
PRTC
)
16.50
-0.30 (-1.79%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PureTech Health plc - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
PureTech to Present at the Leerink Partners Global Healthcare Conference
February 25, 2026
From
PureTech Health plc
Via
Business Wire
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
February 19, 2026
From
PureTech Health plc
Via
Business Wire
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
PureTech Health plc
Via
Business Wire
Earnings Scheduled For April 30, 2025
↗
April 30, 2025
Via
Benzinga
PureTech Appoints Robert Lyne as Chief Executive Officer
December 18, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
December 08, 2025
From
PureTech Health plc
Via
Business Wire
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
December 05, 2025
From
PureTech Health plc
Via
Business Wire
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
October 22, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
September 29, 2025
From
PureTech Health plc
Via
Business Wire
CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday
↗
September 19, 2025
Via
Benzinga
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
September 11, 2025
From
PureTech Health plc
Via
Business Wire
PureTech (PRTC) Q2 2025 Earnings Call Transcript
↗
September 02, 2025
Via
The Motley Fool
Topics
Earnings
PureTech Health Cash Runway Extended
↗
September 02, 2025
Via
The Motley Fool
Earnings Scheduled For August 28, 2025
↗
August 28, 2025
Via
Benzinga
PureTech Health plc – Half-Year Report
August 28, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
August 21, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Health: Notice of Half-Yearly Results
August 18, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 13, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
August 12, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 17, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces Leadership Transition
July 16, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Announces Board Change
July 08, 2025
From
PureTech Health plc
Via
Business Wire
Why This Biotech Stock Just Doubled In A Single Day
↗
June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via
Benzinga
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
June 26, 2025
From
PureTech Health plc
Via
Business Wire
PureTech Health: Results of Annual General Meeting
June 16, 2025
From
PureTech Health plc
Via
Business Wire
PureTech to Present at the Jefferies Global Healthcare Conference
May 22, 2025
From
PureTech Health plc
Via
Business Wire
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
May 20, 2025
From
PureTech
Via
Business Wire
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
May 09, 2025
From
PureTech Health plc
Via
Business Wire
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
May 01, 2025
From
PureTech Health plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
